The dust of national centralized mining plan is settled! "4 + 7" will play the second season this year

In 2018, it was quite painful for pharmaceutical enterprises Bidding price reduction, two vote system, business to value-added, consistency evaluation, knife to knife blood 2019 will be more painful for pharmaceutical enterprises! In the case of bidding procurement, the drug price will no longer show a gentle downward spiral, instead, it will be an avalanche For pharmaceutical enterprises, in the pain is to choose to sink and die or choose to stay dead and posterity? 4 + 7 is just the beginning of the prologue, and the fierce price war is still ahead Just now, the notice of the general office of the State Council on printing and distributing the pilot program of centralized procurement and use of drugs organized by the state (GBF [2019] No 2) was officially issued, which once again clarified the selection of generic drugs corresponding to generic drugs through quality and efficacy consistency evaluation in 11 cities including Beijing, Tianjin, Shanghai, Chongqing, Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu and Xi'an For the selection of pilot varieties, the State shall organize the centralized purchase and use of drugs This basically means that the 4 + 7 just passed this year is only the first season, and the bidding of the second season will be on this year Coincidentally, there is another news that surprises pharmaceutical companies: according to the industry information, two super large provincial health insurance bureaus known as "sharp price reduction" and "no blink of an eye" have organized internal workshops respectively to study the related issues of the new round of drug volume purchase in 2019 Although the detailed rules are not available, people close to the source said that the 4 + 7 price reduction project will become an important reference So, in 2019, what is the background and motivation of national drug bidding procurement? Based on the relevant materials, the author analyzes as follows: drug bidding and price reduction will form a combination fist In terms of price management, on the basis of stock reform, we will shift from extensive management to connotative development and from high-speed development to high-quality development That is to say, we should significantly squeeze out the price of drugs, reduce the proportion of drugs, improve the income of medical services, and optimize the efficiency of medical insurance fund expenditure The bidding and purchasing catalogue is purchased for use and dynamic in and out First, the basic catalogue of bidding and purchasing - medical insurance catalogue will be dynamically adjusted, and there is little hope for the catalogue to be added by all regions Second, the medical insurance catalog will be in line with the auxiliary drug catalog, and the way of "one dozen, one pressure, one push, one pull" will be adopted to strictly restrict the bidding procurement The bidding and purchase of drugs will continue to deepen reform The pilot area of centralized drug procurement organized by the state will be gradually expanded Under the drug procurement mode in 2019, the state will not be excluded from exploring, researching and organizing the formation of new business policies for bidding procurement The era of drug information big data interaction is coming The construction of the national unified platform for drug purchase, distribution and settlement will continue to be improved In the future, the overall data related to drug information will be in-depth mastered from the national level to provide decision-making for the study of the real attributes of drug prices In 2019, what are the trends of drug bidding and purchasing? The author analyzes as follows: low price, close to the base price! ——The conduction effect of 4 + 7 project is expanded In order to compete for the market scale of the non pilot area, the non pilot area will present the situation that enterprises voluntarily reduce prices and hang on the Internet, and the phenomenon that the price reduction range and the final price exceed the price selected in the 4 + 7 project will be everywhere, and this price will be basically close to the red line of the bottom price in the heart of pharmaceutical enterprises The national payment standard for medical insurance may be difficult to issue It is expected that the local government will continue to use the existing medical insurance payment standard mode in different regions Under the background that the drug price has not yet taken on a real look, it is not expected that the unified medical insurance payment standard will be issued temporarily But in the long run, "the patients use the drugs whose price is higher than the payment standard, and the part which is beyond the payment standard shall be paid by the patients themselves; the patients use the drugs whose price is lower than the payment standard, and pay according to the actual price" will become the future trend The "consistency evaluation drug" of hospital procurement presents a "transition" stage As a result of large-scale promotion of consistent evaluation drugs, patients and prescriptions will have to be questioned in clinical aspects Therefore, in the face of diversified consumer demand, there will be a certain transition stage in hospital purchase of consistent evaluation drugs It is difficult to change the status quo of utilitarian "decentralized procurement" In recent two years, a few places have carried out the second and third procurement through bidding, which is not for the sake of public interest to save medical insurance funds, but for the purpose of "monopoly" in the name of bidding: monopoly distributors, monopoly negotiators and monopoly suppliers However, the overall trend of drug procurement is still in the stage of adjustment, and this phenomenon of second and third price negotiation procurement with only low price will still have a large market It has been pointed out that the implementation of centralized drug procurement can achieve win-win results in many ways only when the relationship among medical insurance, pharmaceutical enterprises, hospitals, doctors and patients is well coordinated! At present, the status of medical insurance and patients will be in the first place How to deal with this complex situation of bidding and purchase in pharmaceutical enterprises still needs to be comprehensively studied and judged from the aspects of stock resources cleaning up and rectification at the source, changes in drug bidding methods, changes in clinical medication methods and medical insurance cost control Statement: this opinion only represents the author, not the position of yaozhi.com, welcome to exchange and supplement in the message area; if you need to reprint, please be sure to indicate the author and source of the article.